Using unpaired and paired sample data from the TCGA database, we conducted an in-depth analysis at the mRNA level and observed an upward trend in NUP62 expression across multiple cancer types, including Bladder Urothelial Carcinoma (BLCA), Breast Invasive Carcinoma (BRCA), COAD, Esophageal Carcinoma (ESCA), HNSC, Kidney Renal Clear Cell Carcinoma (KIRC), Kidney Renal Papillary Cell Carcinoma (KIRP), LIHC, Lung Adenocarcinoma (LUAD), LUSC, and Stomach Adenocarcinoma (STAD) (Figures 1A, C). Here, NUP62 is linked to invasive breast carcinoma.